Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Monday, down -7.21% from the previous trading day, before settling in for the closing price of $15.53. Over the past 52 weeks, VRDN has traded in a range of $11.40-$27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -4.36% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -6.58%. With a float of $71.23 million, this company’s outstanding shares have now reached $79.21 million.
In an organization with 96 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -2047.68%, operating margin of -93722.52%, and the pretax margin is -85127.15%.
Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 10.07%, while institutional ownership is 105.28%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -6.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.14% during the next five years compared to 27.64% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 18.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3804.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.96, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.87 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was inferior than the volume of 1.11 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 14.02%. Additionally, its Average True Range was 0.92.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 2.37%, which indicates a significant decrease from 7.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.98% in the past 14 days, which was lower than the 60.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.20, while its 200-day Moving Average is $17.80. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $15.37. Second resistance stands at $16.34. The third major resistance level sits at $16.97. If the price goes on to break the first support level at $13.77, it is likely to go to the next support level at $13.14. The third support level lies at $12.17 if the price breaches the second support level.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
The company with the Market Capitalisation of 1.14 billion has total of 79,213K Shares Outstanding. Its annual sales at the moment are 310 K in contrast with the sum of -237,730 K annual income. Company’s last quarter sales were recorded 90 K and last quarter income was -76,690 K.
